Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Zeria Pharmaceutical Co., Ltd. (4559:JPX), powered by AI.
Zeria Pharmaceutical Co., Ltd. is currently trading at ¥2,108. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Zeria Pharmaceutical Co., Ltd. on Alpha Lenz.
Zeria Pharmaceutical Co., Ltd.'s P/E ratio is 9.4.
“Zeria Pharmaceutical Co., Ltd. trades at a P/E of 9.4 (undervalued) with solid ROE of 11.7%. 3Y revenue CAGR of 13.6% highlights clear growth momentum.”
Ask for details →Zeria Pharmaceutical Co., Ltd. is a prominent entity within the pharmaceutical industry, primarily engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company is distinguished for its focus on gastrointestinal, urological, and detoxification treatments, providing a range of therapeutic drugs aimed at addressing complex medical needs. Beyond prescription medications, Zeria also produces over-the-counter products, expanding its reach to general consumers seeking accessible healthcare solutions. Founded in Japan and deeply rooted in the region, Zeria plays a significant role in the Asian pharmaceutical market, contributing to health advancements through innovation and rigorous scientific inquiry. Its commitment to quality and efficacy positions Zeria as a reliable partner in health, impacting both individual health outcomes and broader public health landscapes. By integrating traditional pharmaceutical methods with cutting-edge research, Zeria Pharmaceutical Co., Ltd. continues to advance in its mission to improve patient lives across varied sectors of healthcare.
“Zeria Pharmaceutical Co., Ltd. trades at a P/E of 9.4 (undervalued) with solid ROE of 11.7%. 3Y revenue CAGR of 13.6% highlights clear growth momentum.”
Ask for details →Zeria Pharmaceutical Co., Ltd. (ticker: 4559) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,746 employees. Market cap is $92.9B.
The current price is 2,108 with a P/E ratio of 9.35x and P/B of 1.04x.
ROE is 11.75% and operating margin is 13.97%. Annual revenue is $87.3B.